UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Cancer discovery, 2015-05, Vol.5 (5), p.475-487

2015

Volltextzugriff (PDF)

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

Pharmacology & therapeutics (Oxford), 2019-01, Vol.193, p.20-30

2019

Volltextzugriff (PDF)

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

Cancer discovery, 2021-08, Vol.11 (8), p.1913-1922

2021

Volltextzugriff (PDF)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Oncogene, 2019-09, Vol.38 (37), p.6399-6413

2019

Volltextzugriff (PDF)

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1199-1206

2018

Volltextzugriff (PDF)

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Nature communications, 2019-08, Vol.10 (1), p.3604-12, Article 3604

2019

Volltextzugriff (PDF)

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2535-2545

2020

Volltextzugriff (PDF)

Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation

Pharmacology & therapeutics (Oxford), 2004-08, Vol.103 (2), p.147-166

2004

Volltextzugriff (PDF)

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Cancer cell, 2013-01, Vol.23 (1), p.121-128

2013

Volltextzugriff (PDF)

Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information

Nucleic acids research, 2022-07, Vol.50 (12), p.e68-e68

2022

Volltextzugriff (PDF)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Cell reports (Cambridge), 2019-06, Vol.27 (12), p.3422-3432.e4

2019

Volltextzugriff (PDF)

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

The Journal of clinical investigation, 2023-08, Vol.133 (16), p.1-16

2023

Volltextzugriff (PDF)

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1 -Positive Non–Small-Cell Lung Cancer

JCO precision oncology, 2017-01 (1), p.1-13

2017

Volltextzugriff (PDF)

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Clinical cancer research, 2018-11, Vol.24 (22), p.5658-5672

2018

Volltextzugriff (PDF)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Nature communications, 2022-10, Vol.13 (1), p.5789-5789, Article 5789

2022

Volltextzugriff (PDF)

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights

Pharmacology & therapeutics (Oxford), 2020-06, Vol.210, p.107522-107522, Article 107522

2020

Volltextzugriff (PDF)

Targeting APOBECs in cancer: It’s about timing

Cancer cell, 2024-04, Vol.42 (4), p.497-501

2024

Volltextzugriff (PDF)

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cancers, 2021-05, Vol.13 (11), p.2666

2021

Volltextzugriff (PDF)

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Cancer research (Chicago, Ill.), 2014-06, Vol.74 (11), p.3146-3156

2014

Volltextzugriff (PDF)

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells

Scientific reports, 2021-02, Vol.11 (1), p.3656-3656, Article 3656

2021

Volltextzugriff (PDF)

Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

Clinical cancer research, 2020-06, Vol.26 (11), p.2441-2443

2020

Volltextzugriff (PDF)

Cycling cancer persister cells arise from lineages with distinct programs

Nature (London), 2021-08, Vol.596 (7873), p.576-582

2021

Volltextzugriff (PDF)

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

Clinical cancer research, 2016-09, Vol.22 (18), p.4585-4593

2016

Volltextzugriff (PDF)

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Clinical cancer research, 2019-11, Vol.25 (22), p.6662-6670

2019

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Englisch
(147)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(72)
Humans
(66)
Oncology
(49)
Animals
(34)
Mutation
(34)
Lung Neoplasms - Genetics
(33)
Lung Neoplasms - Drug Therapy
(28)
Mice
(27)
Cell Line, Tumor
(22)
Protein Kinase Inhibitors - Pharmacology
(22)
Carcinoma, Non-Small-Cell Lung - Genetics
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)
Cell Biology
(18)
Lung Cancer
(17)
Female
(16)
Lung Neoplasms - Pathology
(16)
Tumors
(16)
Drug Resistance, Neoplasm - Genetics
(14)
Erbb Receptors - Genetics
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1 -Positive Non–Small-Cell Lung Cancer

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights

Targeting APOBECs in cancer: It’s about timing

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells

Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

Cycling cancer persister cells arise from lineages with distinct programs

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Suchergebnisse filtern